SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats

Ohara, Tatsuo; Tanaka, Kenichi; Fukaya, Hiroaki; Demura, Nobutaka; Iimura, Akiko; Seno, Norihisa

doi:10.1016/s0166-4328(97)86076-7

Cited by 24 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rivastigmine treatment in male Wistar rats with ibotenic acid lesions of the basal forebrain, at doses of 0.1 and 0.2 mg/kg, reversed deficits in water-maze performance (Ohara et al, 1997b). Furthermore, acute doses of rivastigmine (0.3-1.0 mg/kg) in male Swiss mice exposed to CO 2 -induced hippocampal neurodegeneration either before CO 2 or 20 min before behavioral testing reversed memory impairments in a Ymaze spontaneous alternation task (Meunier et al, 2006a).…”

Section: Rivastigminementioning

confidence: 86%

Anti-dementia drugs and hippocampal-dependent memory in rodents

Yuede¹,

Dong²,

Csernansky³

2007

Behavioural Pharmacology

View full text Add to dashboard Cite

Abnormalities in hippocampal structure and function are characteristics of early Alzheimer's disease (AD). Behavioral tests measuring hippocampal-dependent memory in rodents are often used to evaluate novel treatments for AD and other dementias. In this study, we review the effects of drugs marketed for the treatment of AD, such as the acetylcholinesterase inhibitors, donepezil, rivastigmine, galantamine and the N-methyl-D-aspartic acid antagonist, memantine, in rodent models of memory impairment. We also briefly describe the effects of novel treatments for cognitive impairment in rodent models of memory impairment, and discuss issues concerning the selection of the animal model and behavioral tests. Suggestions for future research are offered.

show abstract

Section: Rivastigminementioning

confidence: 86%

Anti-dementia drugs and hippocampal-dependent memory in rodents

Yuede¹,

Dong²,

Csernansky³

2007

Behavioural Pharmacology

View full text Add to dashboard Cite

show abstract

“…The highest dose of rivastigmine (1.0 mg kg −1 day −1 ), however, did not show additional benefit, and even exerted a negative impact on MWM performance. In previous studies, rivastigmine antagonized chemically (Enz et al 1989;Bejar et al 1999) or lesion-induced (Ohara et al 1997b), and even age-dependent deficits in MWM learning (Ohara et al 1997a). Besides the standard water maze paradigm, a multitude of test settings and parameters was employed to investigate cholinomimetic symptomatic efficacy of rivastigmine in rodent models (Ueki and Miyoshi 1991;Niigawa et al 1995;Ballard and McAllister 1999).…”

Section: Discussionmentioning

confidence: 99%

Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Here, we indicate that chronic administration of selective acetylcholinesterase inhibitors that are approved for AD treatment, at a dosage effective in increasing acetylcholine release in the hippocampus and cortex of aged rats (21), restores ChaT activity and performance in the water maze test in EAE rats. An up-regulation of ChaT activity in the brain has been obtained with different acetylcholinesterase inhibitors, such as ENA 713 (47,48), tacrine (49), and TAK-147 (50). Mechanisms through which acetylcholinesterase inhibitors up-regulate ChaT activity are not known.…”

Section: Cns Inflammation and The Cholinergic System Of The Basal Formentioning

confidence: 99%

Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats

D’Intino

Paradisi

Fernández

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Clinical symptoms in multiple sclerosis include cognitive dysfunction. Difficulties in learning and remembering new information represent the most common cognitive deficit and are associated with a general and progressive brain pathology. Possible pathogenetic mechanisms for neuronal damage such as neuroprotective strategies are under active investigation also in experimental allergic encephalomyelitis, the most widely used experimental model for multiple sclerosis. In this paper we demonstrate that a selective deficit in learning and memory performance, as investigated by the Morris water maze test, is a consistent feature in rat encephalomyelitis, which correlates with a decline in choline acetyltransferase activity and nerve growth factor mRNA level in cerebral cortex, hippocampus, and basal forebrain. Treatment aimed to restore acetylcholine content through chronic administration of selective acetylcholinesterase inhibitors (rivastigmine and donepezil) restores cognitive performance, choline acetyltransferase activity, and nerve growth factor mRNA expression.choline acetyltransferase ͉ multiple sclerosis ͉ learning and memory ͉ water maze ͉ acetylcholinesterase inhibitors

show abstract

SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats

Cited by 24 publications

References 20 publications

Anti-dementia drugs and hippocampal-dependent memory in rodents

Anti-dementia drugs and hippocampal-dependent memory in rodents

Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats

Contact Info

Product

Resources

About